Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis

Area of Science:

• Pediatric Rheumatology
• Immunology
• Dermatology

Background:

• Juvenile dermatomyositis (JDM) is the most prevalent form of juvenile idiopathic inflammatory myopathy.
• It presents a significant challenge in pediatric rheumatology, often requiring long-term management.
• Standard treatments may not be effective for all patients.

Observation:

• A case report details a child with steroid-dependent JDM.
• The patient was refractory to hydroxychloroquine and subcutaneous methotrexate.
• Systemic reactions occurred with intravenous immunoglobulin (IVIG).

Findings:

• Successful treatment was achieved using subcutaneous immunoglobulin (SCIG).
• SCIG demonstrated a favorable safety profile with a low incidence of adverse effects.
• This therapeutic approach eliminated the need for hospital admission.

Implications:

• Subcutaneous immunoglobulin offers a viable alternative for refractory JDM cases.
• This treatment can reduce healthcare costs and improve patient quality of life.
• Minimizing missed school days is a significant benefit for affected children.